Restrictive or obstructive pulmonary disease
History of clinically severe lung disease, asthma, or chronic obstructive pulmonary disease (COPD) requiring emergency management and/or hospitalization in the last year
Pulmonary disease (e.g. COPD, asthma, etc) that is not controlled (moderate to severe symptoms) with current medication
Pulmonary disease requiring chronic medical therapy, unrelated to underlying cancer
Severe chronic obstructive pulmonary disease (COPD) defined as disease requiring an inpatient stay for respiratory deterioration within the past  months
Pulmonary: no requirement for supplemental oxygen and no evidence of moderate-severe chronic obstructive pulmonary disease (COPD) by pulmonary function tests (PFTs)
Uncontrolled medical conditions including diabetes, heart failure, chronic obstructive pulmonary disease (COPD), ulcerative colitis, or Crohns disease
If they have New York Heart Association (NYHA) class  or : myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding  months; or any other intercurrent medical condition that contraindicates treatment with sEphBHSA or places the patient at undue risk for treatment related complications
Pulmonary disease which, in the opinion of the investigator, may impair the patient's respiratory tolerance to moderate pulmonary fluid overload (e.g., interstitial lung disease, severe chronic obstructive pulmonary disease)
New York Heart Association class  or  heart failure; myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis, or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding  months; or any other intercurrent medical condition that contraindicates treatment with sEPHB-HSA or places the patient at undue risk for treatment related complications
Uncontrolled chronic obstructive pulmonary disease or previous known pulmonary fibrosis
Chronic medical illness including diabetes with the use of insulin, hemoglobin Ac >  (study physician discretion), heart disease diagnosed by angiogram, chronic obstructive pulmonary disease (COPD) diagnosed by pulmonary function testing and requiring an oxygen supply
History of clinically significant chronic obstructive pulmonary disease (COPD), asthma, or other chronic lung disease.
Known severe chronic obstructive pulmonary disease or asthma
Known moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, or pulmonary fibrosis
Pulmonary disease (e.g. COPD, asthma, etc) that is not controlled (moderate to severe symptoms) with current medication
Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis
Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis, severe Chronic obstructive pulmonary disease (COPD) requiring >  hospitalization in the past year
Known history of clinically significant active COPD, or other moderate-to-severe chronic respiratory illness present within  months.
Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis
Patients with pre-existing uncontrolled pulmonary disease will be excluded; uncontrolled refers to patients having had at least one hospitalization due to pulmonary disease (for example, asthma, chronic obstructive pulmonary disease) within the  months prior to enrollment in the study; patients with previous history of pneumonitis will be excluded
Has known history of, or any evidence of active, non-infectious pneumonitis that required steroids (steroid treatment of chronic obstructive pulmonary disease [COPD] or asthma allowed)
Has New York Heart Association (NYHA) class  or , myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding  months; or any other intercurrent medical condition that contraindicates treatment with sEphBHSA or pembrolizumab (MK-) or places the patient at undue risk for treatment related complications
Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, chronic obstructive pulmonary disease [COPD])
Pulmonary disease: severe chronic obstructive lung disease, or symptomatic restrictive lung disease
Serious medical conditions (congestive heart failure [CHF], angina, diabetes mellitus type , chronic obstructive pulmonary disease [COPD], bleeding diathesis)
Known history of clinically significant active COPD, or other moderate-to-severe chronic respiratory illness present within  months.
Chronic Obstructive Pulmonary Disease, defined as being associated with a hospitalization for pneumonia or respiratory decompensation within  months of diagnosis; this does not include obstruction from tumor
If they have New York Heart Association (NYHA) class  or ; myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding  months; or any other intercurrent medical condition that contraindicates treatment with sEphB-HSA or places the patient at undue risk for treatment related complications
Severe chronic obstructive pulmonary disease (COPD) with hypoxemia
Known history of clinically significant active COPD, or other moderate-to-severe chronic respiratory illness present within  months.
History of chronic obstructive pulmonary disease (COPD) or other chronic pulmonary disease requiring systemic steroid therapy, oxygen, or hospitalization
Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis
Severe chronic obstructive pulmonary disease (COPD) requiring >  hospitalizations in the past year
Severe chronic obstructive pulmonary disease requiring oxygen supplementation
Patients who require chronic oxygen therapy for chronic obstructive pulmonary disease or pleural effusions (malignant or benign)
History or other evidence of chronic pulmonary disease associated with functional limitation
History or other evidence of chronic pulmonary disease associated with functional limitation
Clinically significant lung disease including known history or evidence of interstitial lung disease or chronic obstructive pulmonary disease (COPD) that requires oxygen therapy
Presentation of pulmonary insufficiency or clinically evident chronic obstructive pulmonary disease
Evidence of pulmonary insufficiency or clinically evident chronic obstructive pulmonary disease
Active and ongoing steroid use, except for non-systemically absorbed treatments (such as inhaled or topical steroid therapy for asthma, chronic obstructive pulmonary disease [COPD], allergic rhinitis)
Known chronic obstructive pulmonary disease (COPD) OR moderate or severe persistent asthma within the past  years
Inflammatory lung disease including moderate and severe asthma and chronic obstructive pulmonary disease (COPD) requiring chronic medical therapy.
Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, chronic obstructive pulmonary disease [COPD])
Subjects with a history of interstitial lung disease or lung disease that has required intubation in the past (i.e. such as asthma or chronic obstructive pulmonary disease [COPD]); patients requiring continuous supplemental oxygen are excluded
Any history of symptomatic pulmonary compromise, such as chronic obstructive pulmonary disease
Concurrent major medical conditions, such as uncontrolled hypertension, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary disease, autoimmune disease, adrenal insufficiency, or prior allogeneic organ transplant requiring chronic immunosuppressive therapy, including systemic glucocorticoid treatment or replacement therapy
Severe hyperactive airway disease (chronic obstructive pulmonary disease, asthma)
Severe chronic obstructive or other pulmonary disease with hypoxemia
Evidence of chronic obstructive pulmonary disease
Participants with diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding  months, or any other intercurrent medical condition that contraindicates treatment with sEphB-HSA or places the participant at undue risk for treatment related complications
Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, chronic obstructive pulmonary disease [COPD])
a short duration (<  days) of systemic corticosteroids e.g., of chronic obstructive pulmonary disease, or as an antiemetic corresponding at maximum to the anti-inflammatory potency of  mg dexamethasone for treatment;
Asthma or chronic obstructive pulmonary disease (COPD) requiring daily medication.
Inflammatory lung disease including moderate and severe asthma and chronic obstructive pulmonary disease (COPD) requiring chronic medical therapy.
Patients with severe cardiac disease including symptomatic congestive heart failure, unstable angina, or have experience an acute myocardial infarction within the past  months; please note: patients with chronic obstructive pulmonary disease (COPD) are not excluded
Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, pulmonary fibrosis, and pulmonary arterial hypotension.
Chronic steroid or immunosuppressive therapy (except for low dose corticosteroids for chronic obstructive pulmonary disease [COPD] or topical steroids, which are allowed)
Known moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary fibrosis
Patient has a history of significant cardiovascular, neurological, endocrine, gastrointestinal, respiratory, or inflammatory illness including recent myocardial infarction (within  months)or stroke; hypertension requiring > medications for adequate control; diabetes mellitus with > episodes of ketoacidosis in the preceding  months; or chronic obstructive pulmonary disease (COPD) requiring > hospitalizations in the preceding  months.
Chronic obstructive pulmonary disease (COPD) exacerbation at the time of study enrollment.
Severe chronic obstructive pulmonary disease (COPD) by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging system
Subjects on supplemental oxygen or history of chronic obstructive pulmonary disease (COPD)
Severe chronic obstructive pulmonary disease (COPD) requiring oxygen dependence, as this is a contraindication of EMST
Pulmonary conditions such as chronic obstructive pulmonary disease, emphysema, interstitial lung disease, use of supplemental oxygen
Active or symptomatic cardiopulmonary disease (myocardial infarction <  month, heart failure >= New York Heart Association [NYHA] II, atrial fibrillation with poor rate control, high grade atrioventricular [AV] block, obstructive valvular disease, chronic obstructive pulmonary disease [COPD])
Other causes of cachexia such as: liver disease (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >  x normal levels); renal failure (creatinine > . mg/dL), untreated thyroid disease, class III-IV congestive heart failure (CHF), acquired immune deficiency syndrome (AIDS), other cancer diagnosed within the past  years other than non-melanoma skin cancer, severe chronic obstructive pulmonary disease (COPD) requiring use of home oxygen (O)
History or current clinical evidence of moderate -to-severe obstructive pulmonary disease or reactive airway diseases (i.e.: asthma) requiring therapy
History of severe chronic obstructive pulmonary disease (COPD) and resting oxygen saturation (SpO) < %
Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) exacerbation at the time of study enrollment
Diagnosed with chronic obstructive pulmonary disease (COPD) oxygen dependent
History or current clinical evidence of moderate-to-severe obstructive pulmonary disease or reactive airway diseases (i.e. asthma) requiring therapy
Has a serious cardiopulmonary medical condition (including cardiovascular disease, congestive heart failure [CHF], chronic obstructive pulmonary disease [COPD], restrictive lung disease, interstitial lung disease, asthma, acute or chronic bronchitis, cystic fibrosis, pneumonia, tuberculosis, pneumoconiosis, pulmonary hypertension, pulmonary embolism, pleural effusion, pneumothorax, obesity hyperventilation syndrome, neuromuscular lung disease)
Known history of chronic pulmonary disease
Physician-diagnosed chronic obstructive pulmonary disease (COPD)
Severe obstructive lung disease (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage III or IV, FEV < % predicted)
Patients with stage II chronic obstructive pulmonary disease (COPD) or worse, per Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification
Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease [COPD] requiring oxygen)
Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease [COPD])
Ongoing acute or chronic pulmonary bronchospastic disease, including a history of chronic obstructive pulmonary disease or asthma, with an exacerbation within the past year
Pre-existing respiratory conditions:\r\n* Severe chronic obstructive pulmonary disease (including chronic bronchitis and/or emphysema)\r\n* Other respiratory or lung conditions, which would place the participant at risk\r\n* Presence of any other significant cardiac or pulmonary symptoms, such as moderate or severe dyspnea on exertion, orthopnea, or paroxysmal nocturnal dyspnea
Patients must have pulmonary function as defined below:\r\n* Abnormal pulmonary function test within  months of study entry\r\n* Prior radiation to the lungs\r\n* Prior surgical resection of lung tissue (i.e. wedge resection, lobectomy, or pneumonectomy)\r\n* Clinical diagnosis of chronic obstructive pulmonary disease (COPD) or emphysema\r\n* Ongoing oxygen use
Presence of significant medical illness: autoimmune/inflammatory diseases, cardiopulmonary disorders (i.e., angina, congestive heart failure, severe chronic obstructive pulmonary disease [COPD]), uncontrolled endocrine disorders (i.e., hypothyroidism, diabetes), vestibular neuritis, Meniere's syndrome, benign paroxysmal positional vertigo, or known or previously diagnosed structural disorder of the peripheral vestibular system
Immune system disorders, pulmonary diseases (e.g., asthma within the prior  years, acute bronchitis within  year, chronic obstructive pulmonary disease [COPD], chronic bronchitis, and restrictive lung disease), clinically diagnosed kidney or liver diseases, or any other medical disorders that will increase the risk from bronchoscopy, affect biomarker data, or increase risk of an adverse effect from e-cig use; all subjects are screened by a pulmonologist obtaining a medical history and a physical examination (heart, lungs and oral cavity) to ensure no increased risk from bronchoscopy or e-cig use
recent history (past  months) of Chronic Obstructive Pulmonary Disease (COPD), cancer (any non-dermatologic), or uncontrolled diabetes mellitus
pre-existing clinically significant dysfunction of the heart or Chronic Obstructive Pulmonary Disease (COPD)